LIA
EW icon

Luken Investment Analytics’s Edwards Lifesciences EW Stock Holding History

Luken Investment Analytics’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$426 – 256
2025
Q4 		$426 Buy
+5
New +$410 ﹤0.01% 320

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Luken Investment Analytics's EW Position: Q1 2026 in Review

Luken Investment Analytics sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 5 shares — an estimated $426 sold.

Luken Investment Analytics first reported a position in EW in Q4 2025 and held it in 1 quarter. The position peaked at $426 in Q4 2025. 1,292 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Luken Investment Analytics reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • Luken Investment Analytics sold 5 Edwards Lifesciences shares in Q1 2026, an estimated $426.
  • Luken Investment Analytics first reported a position in Edwards Lifesciences in Q4 2025 and held it in 1 quarter.
  • Luken Investment Analytics's Edwards Lifesciences position peaked at $426 in Q4 2025.
  • 1,292 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Luken Investment Analytics's 13F filing for Q1 2026, filed 12 May 2026.